AWARD NUMBER: W81XWH-13-1-0380

TITLE: "The Role of the New mTOR complex, MTORC2, in Autism Spectrum Disorders"

PRINCIPAL INVESTIGATOR: Mauro Costa-Mattioli

CONTRACTING ORGANIZATION: Baylor College of Medicine

REPORT DATE: October 2014

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> <i>OMB No. 0704-0188</i>	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2013 - 29 Sep 2014	
4. TITLE AND SUBTITLE "THE ROLE OF THE NEW MTOR COMPLEX, MTORC2, IN AUTISM SPECTRUM DISORDERS"				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-13-1-0380	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Mauro Costa-Mattioli E-Mail: mcmattioli@cns.bcm.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Baylor College of Medicine One Baylor Plaza Houston, TX 77030				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The goal of my DOD-supported research is determine the role of the new mTOR complex (mTORC2) in Autism Spectrum Disorder (ASD). ASD individuals exhibit impaired social interactions, seizures and abnormal repetitive behavior. In addition, 70-80% of autistic individuals suffer from mental retardation. Autism is a heritable genetically heterogeneous disorder and mutations in negative regulators of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway, such as PTEN were associated with ASD. Here, we show that in the hippocampus of Pten fb-KO mice – where Pten is conditionally deleted in the murine forebrain – the activity of both mTORC1 and mTORC2 is increased. In addition, Pten fb-KO mice exhibit seizures, learning and memory and social deficits. Our remarkable preliminary data show that genetic inhibition of mTORC2 activity in Pten-deficient mice significantly promotes survival. In addition, Pten-riCTOR fb- double KO (DKO) mice, in which mTORC2 activity is restored to normal levels, EEG seizures, learning and memory as well as social phenotypes, are all rescued. In the second year, we will study the molecular mechanism underlying this process. These insights hold the promise for new treatment of ASD.					
15. SUBJECT TERMS Autism Spectrum Disorder (ASD), mTORC2, mTORC1, protein synthesis, actin polymerization, mitochondria function, long-term memory, social behaviors, repetitive behaviors, and seizures.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	4
2. Keywords.....	4
3. Overall Project Summary.....	4
4. Key Research Accomplishments.....	6
5. Conclusion.....	6
6. Publications, Abstracts, and Presentations.....	7
7. Inventions, Patents and Licenses.....	7
8. Reportable Outcomes.....	7
9. Other Achievements.....	7
10. References.....	7
11. Appendices.....	8

1. Introduction:

Autism represents a heterogeneous group of disorders, which are defined as “autism spectrum disorders” (ASDs). ASD individuals exhibit common features such as impaired social interactions, language and communication, and abnormal repetitive behavior. In addition, 70-80% of autistic individuals suffer from mental retardation¹⁻³. The major goal of this award is to determine the role of mTORC2 in two mouse models of ASD. Recently, we have shown that mTORC2 plays a crucial role in long-term memory formation⁴. Briefly, mice lacking mTORC2 showed impaired long-lasting changes in synaptic strength (L-LTP) as well as impaired long-term memory (LTM). In addition, we have found that by promoting mTORC2 activity, with a new agent A-443654, it facilitates L-LTP and enhances long-term memory formation in WT mice. Interestingly, mTORC2 activity is altered in both ASD patients and ASD mouse models harboring mutation in *Tsc* and *Pten*^{5,6}. Hence, in this proposal we will test the hypothesis that the neurological dysfunction in several ASD mouse models is caused by dysregulation of mTORC2 rather than mTORC1 activity.

2. Keywords: Autism Spectrum Disorder (ASD), mTORC2, mTORC1, protein synthesis, actin polymerization, mitochondria function, long-term memory, social behaviors, repetitive behaviors, seizures.

3. Overall Project Summary. We have generated a remarkable amount of progress regarding specific Aim 2. Given that mTORC2 activity is increased in *Pten*-deficient mice^{7,8}, we wondered whether its reduction could rescue the ASD-like cellular and behavioral phenotypes in *PTEN*-deficient mice. We cannot block mTORC2 activity pharmacologically because specific inhibitors of mTORC2 are not available. Hence, we conditionally deleted *Pten* and/or *riCTOR* in the murine forebrain using the Cre/lox system. Because the α CaMKII promoter is inactive before birth^{9,10}, this manipulation rules out possible developmental defects caused by the lack of *pten* and *riCTOR*. We thus generated and studied the followings experimental mice: WT mice, *Pten* forebrain-specific knockout (here defined as *Pten* fb-KO), *Pten-riCTOR* forebrain-specific double knockout (here defined as *Pten-Rictor* fb-DKO). According to our preliminary data, mTORC2-mediated phosphorylation of Akt at Ser473 [an established readout of mTORC2 activity⁶ and mTORC1-mediated phosphorylation of ribosome protein S6 [a well-established readout of mTORC1 activity¹¹] were both increase in the hippocampus of *Pten* fb-KO (**Fig. 1**). By contrast, in *Pten-riCTOR* fb-DKO only mTORC1 activity is up-regulated (**Fig. 1**). Hence, conditional deletion of *riCTOR* selectively blocks mTORC2 activity in *Pten*-deficient neurons.

Kaplan-Meier analysis of animal survival revealed a dramatic decreased in survival in *Pten* fb-KO mice (**Fig. 2**; *Pten* fb-KO mice die at an age of 52.4 +/- 8 days), which was remarkably prolonged by genetically inhibiting mTORC2 (**Fig. 2**; *Pten-Rictor* fb-DKO die at an age of 119.4 +/- 25). Hence, inhibition of mTORC2 in *Pten*-deficient mice prolongs their survival.

Because patients with *Pten* mutations exhibit seizures, we next analyzed spontaneous seizures and abnormal electroencephalogram (EEG) activity. We found that *Pten* fb-KO mice show abnormal EEG as well as tonic-clonic seizures (**Fig. 3**). By contrast, while *Pten-Rictor* fb-DKO showed some abnormalities (spikes) in the EEG pattern, they did not show tonic-clonic and/or EEG seizures (**Fig. 3**). Thus, inhibition of mTORC2 suppresses the seizures EEG phenotype in *Pten*-deficient mice.

Fig. 3. Genetic inhibition of mTORC2 suppresses EEG seizures *Pten* fb-KO mice. Traces from bilateral cortical electrodes (Left hemisphere, L, Right hemisphere, R) show abnormal EEG seizures in freely moving *Pten* fb-KO mice (**a**; n=2), which are suppressed in *Pten-Rictor* fb-DKO mice (**b**; n=2).

Finally, we measured learning and memory and social phenotypes in *Pten* fb-KO mice and *Pten-Rictor* fb-DKO. As expected, *Pten* fb-KO mice showed impaired long-term fear memory (**Fig. 4a**) and deficient social interaction (**Fig. 4b**). However, both long-term memory and social deficits are rescued in *Pten-Rictor* fb-DKO (**Fig. 4a-b**). We are currently measuring whether direct social interaction and repetitive behaviors are also rescued by inhibition of mTORC2 in *Pten*-deficient mice.

Fig. 4. Genetic inhibition of mTORC2 rescues the deficient long-term memory and social novelty in *Pten* fb-KO mice. **a**, For contextual fear conditioning, freezing times were recorded 24 hr after conditioning. As compared to control mice (n=29), *Pten* fb-KO mice show deficient freezing 24 hr after training, indicating that their long-term memory is impaired. In *Pten-riCTOR* fb-DKO mice, freezing levels are similar to those observed in WT mice, indicating that their long-term memory is restored. **b**, Social behavior test: time spent interacting with either a stranger or familiar mouse. WT mice spent most of the time interacting with the stranger mouse but *Pten* fb-KO mice spent equal time interacting with the familiar or strange mouse, indicating that social behavior is impaired in these mice. Like WT mice, *Pten-riCTOR* fb-KO mice spent more time interacting with the stranger mouse, indicating that social behavior is restored.

The goal of subaim-2 was to increase mTORC2 activity by treating *Tsc2*-deficient mice with the mTORC2 agonist A-443654⁴. We have obtained *Tsc2* floxed mice but after breeding we noticed that they were in a mix background. Hence, to avoid any behavioral artifacts due to mixed genetic background, we decided to backcross these mice to C57BL6 mice to obtain a pure background. It is noteworthy that genetic background may alter behavior of autistic mice¹². We have now obtained mice in a pure background and these mice are now being crossed with *CamKII-Cre*. In the next few months or so, *Tsc2*-deficient mice will be treated with vehicle and A-443654 and behavior and electrophysiology will be performed in these mice, as discussed in the proposal.

4. Key Research Accomplishment

- We developed a way to specifically block mTORC2 activity in *Pten*-deficient mice.
- Genetic deletion of mTORC2 prolongs the survival of *Pten*-deficient mice.
- Genetic deletion of mTORC2 dramatically attenuates seizures in *Pten*-deficient mice.
- Genetic deletion of mTORC2 improves cognitive and social phenotypes in *Pten*-deficient mice.

5. Conclusion

It has been proposed that the increased mTORC1 in *Pten*-deficient or *Tsc*-deficient mice causes the cellular and behavioral phenotypes associated with ASD¹³⁻¹⁹. Our new data challenge this view and posit that the neurological dysfunction in ASD, at least in the *Pten*-ASD mouse model, is caused by dysregulation of mTORC2. Hence, these preliminary data are very important since they identified a new signaling pathway involved in ASD and seizure disorders that could be targeted and lead to the development of new treatments for ASD and seizure disorders.

Future experiments: We will study the precise mechanism by which mTORC2 suppresses *Pten*-mediated cellular and behavioral phenotypes. We will emphasize in two major mechanisms. First, given that mTORC2 regulates actin polymerization, we will measure changes in actin polymerization in *Pten* fb-KO and *Pten-riCTOR* fb-DKO mice. Second, given that *Pten* and mTORC2 both are localized in mitochondria, we will determine whether *Pten*-deficient brains exhibit impaired mitochondria respiration and such an impairment is rescued in *Pten-riCTOR* fb-DKO brain.

In addition, we will measure whether inhibitory/excitatory balance is disrupted in *Pten* fb-KO and rescued in *Pten-riCTOR* fb-DKO mice.

Finally, we will start to characterize the vehicle-treated and A-443654-treated *Tsc*-deficient mice in behavior and electrophysiology.

6. Publications

Some of these data described above were presented in a recent symposium: “Catastrophic Epilepsy” at the Neurological Research Institute (NRI), Houston, Texas

7. Inventions, Patents and Licenses.

Nothing to report

8. Reportable Outcome

Nothing to report

9. Other achievements

We developed forebrain-specific rictor-Pten double KO mice.

10. References

- 1 Fombonne, E. The epidemiology of autism: a review. *Psychol Med* **29**, 769-786 (1999).
- 2 Mefford, H. C., Batshaw, M. L. & Hoffman, E. P. Genomics, intellectual disability, and autism. *N Engl J Med* **366**, 733-743, doi:10.1056/NEJMra1114194 (2012).
- 3 Toro, R. *et al.* Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. *Trends Genet* **26**, 363-372, doi:S0168-9525(10)00107-1 [pii]10.1016/j.tig.2010.05.007 (2010).
- 4 Huang, W. *et al.* mTORC2 controls actin polymerization required for consolidation of long-term memory. *Nat Neurosci* **16**, 441-448, doi:10.1038/nn.3351 (2013).
- 5 Buffington, S. A., Huang, W. & Costa-Mattioli, M. Translational control in synaptic plasticity and cognitive dysfunction. *Annu Rev Neurosci* **37**, 17-38, doi:10.1146/annurev-neuro-071013-014100 (2014).
- 6 Costa-Mattioli, M. & Monteggia, L. M. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. *Nat Neurosci* **16**, 1537-1543, doi:10.1038/nn.3546 (2013).
- 7 Kwon, C. H. *et al.* Pten regulates neuronal arborization and social interaction in mice. *Neuron* **50**, 377-388, doi:S0896-6273(06)00220-0 [pii]10.1016/j.neuron.2006.03.023 (2006).
- 8 Zhou, J. *et al.* Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. *J Neurosci* **29**, 1773-1783, doi:29/6/1773 [pii]10.1523/JNEUROSCI.5685-08.2009 (2009).
- 9 Mayford, M. *et al.* Control of memory formation through regulated expression of a CaMKII transgene. *Science* **274**, 1678-1683 (1996).
- 10 Tsien, J. Z. *et al.* Subregion- and cell type-restricted gene knockout in mouse brain. *Cell* **87**, 1317-1326 (1996).
- 11 Ma, X. M. & Blenis, J. Molecular mechanisms of mTOR-mediated translational control. *Nat Rev Mol Cell Biol* **10**, 307-318, doi:nrm2672 [pii]10.1038/nrm2672 (2009).
- 12 Moy, S. S. *et al.* Social approach in genetically engineered mouse lines relevant to autism. *Genes Brain Behav* **8**, 129-142, doi:10.1111/j.1601-183X.2008.00452.x (2009).
- 13 Ehninger, D. *et al.* Reversal of learning deficits in a Tsc2(+/-) mouse model of tuberous sclerosis. *Nat Med* (2008).
- 14 Ehninger, D., de Vries, P. J. & Silva, A. J. From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. *J Intellect Disabil Res* **53**, 838-851, doi:JIR1208 [pii]10.1111/j.1365-2788.2009.01208.x (2009).
- 15 Ehninger, D. & Silva, A. J. Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders. *Trends Mol Med* **17**, 78-87, doi:S1471-4914(10)00148-6 [pii]10.1016/j.molmed.2010.10.002 (2011).
- 16 Zhou, J. & Parada, L. F. PTEN signaling in autism spectrum disorders. *Curr Opin Neurobiol*, doi:S0959-4388(12)00083-9 [pii]10.1016/j.conb.2012.05.004 (2012).

- 17 Carson, R. P., Van Nielen, D. L., Winzenburger, P. A. & Ess, K. C. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin. *Neurobiol Dis* **45**, 369-380, doi:S0969-9961(11)00290-7 [pii]10.1016/j.nbd.2011.08.024 (2012).
- 18 Tsai, P. T. *et al.* Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. *Nature* **488**, 647-651, doi:nature11310 [pii]10.1038/nature11310 (2012).
- 19 Wong, M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies. *Epilepsia* **51**, 27-36, doi:EPI2341 [pii]10.1111/j.1528-1167.2009.02341.x (2011).

11. Appendices

N/A